Alzheimer's disease is the most common cause of dementia, and it affects over 7 million people in the United States alone.

GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...